Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard...
Gespeichert in:
| Veröffentlicht in: | JACC. Heart failure 2020-10, Vol.8 (10), p.800-810 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 810 |
|---|---|
| container_issue | 10 |
| container_start_page | 800 |
| container_title | JACC. Heart failure |
| container_volume | 8 |
| creator | Docherty, Kieran F Vaduganathan, Muthiah Solomon, Scott D McMurray, John J V |
| description | Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard angiotensin-converting enzyme inhibitor. In the 5 years since the publication of the results of PARADIGM-HF, further insight has been gained into integrating a neprilysin inhibitor into a comprehensive multidrug regimen, including a renin-angiotensin aldosterone system (RAS) blocker. This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integration of sacubitril/valsartan among patients with heart failure with reduced ejection fraction. |
| doi_str_mv | 10.1016/j.jchf.2020.06.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2448414065</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-db902c0ed97908f86e1a86df56069bc7a8d15c2ed41440e422388d34890d7dab3</originalsourceid><addsrcrecordid>eNpVUNtKw0AQXUSxpfYHfJA8-pJ0b9lMfBBC7Q3qBW_gU9hkN3ZLmtRsIvTvXbEWnZcznDlzzjAInRMcEEzEaB2s81URUExxgEXg4Aj1KSXMJxFEx4c-intoaO0au4KQAMAp6jGGMSeE99HkSeZdZtrGlKNXWVrZtLK68u701jE7aypvUa2ME5i68kLvTcvGeknR6sZ7SB6Tm8Xs1p9Pz9BJ4Zb1cI8D9DKdPI_n_vJ-thgnS39LhWh9lcWY5lirOIoxFCA0kSBUEQos4iyPJCgS5lQrTjjHmlPKABTjEGMVKZmxAbr-8d122UarXFdtI8vU3bqRzS6tpUn_TyqzSt_rzxSARUBDZ3C5N2jqj07bNt0Ym-uylJWuO5tSzsGFY_EtvfibdQj5_R37Aj7bceA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448414065</pqid></control><display><type>article</type><title>Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Docherty, Kieran F ; Vaduganathan, Muthiah ; Solomon, Scott D ; McMurray, John J V</creator><creatorcontrib>Docherty, Kieran F ; Vaduganathan, Muthiah ; Solomon, Scott D ; McMurray, John J V</creatorcontrib><description>Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard angiotensin-converting enzyme inhibitor. In the 5 years since the publication of the results of PARADIGM-HF, further insight has been gained into integrating a neprilysin inhibitor into a comprehensive multidrug regimen, including a renin-angiotensin aldosterone system (RAS) blocker. This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integration of sacubitril/valsartan among patients with heart failure with reduced ejection fraction.</description><identifier>ISSN: 2213-1779</identifier><identifier>EISSN: 2213-1787</identifier><identifier>DOI: 10.1016/j.jchf.2020.06.020</identifier><identifier>PMID: 33004114</identifier><language>eng</language><publisher>United States</publisher><subject>Aminobutyrates ; Angiotensin Receptor Antagonists - therapeutic use ; Biphenyl Compounds ; Drug Combinations ; Heart Failure - drug therapy ; Humans ; Neprilysin - therapeutic use ; Stroke Volume ; Valsartan - therapeutic use</subject><ispartof>JACC. Heart failure, 2020-10, Vol.8 (10), p.800-810</ispartof><rights>Copyright © 2020. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33004114$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Docherty, Kieran F</creatorcontrib><creatorcontrib>Vaduganathan, Muthiah</creatorcontrib><creatorcontrib>Solomon, Scott D</creatorcontrib><creatorcontrib>McMurray, John J V</creatorcontrib><title>Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF</title><title>JACC. Heart failure</title><addtitle>JACC Heart Fail</addtitle><description>Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard angiotensin-converting enzyme inhibitor. In the 5 years since the publication of the results of PARADIGM-HF, further insight has been gained into integrating a neprilysin inhibitor into a comprehensive multidrug regimen, including a renin-angiotensin aldosterone system (RAS) blocker. This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integration of sacubitril/valsartan among patients with heart failure with reduced ejection fraction.</description><subject>Aminobutyrates</subject><subject>Angiotensin Receptor Antagonists - therapeutic use</subject><subject>Biphenyl Compounds</subject><subject>Drug Combinations</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Neprilysin - therapeutic use</subject><subject>Stroke Volume</subject><subject>Valsartan - therapeutic use</subject><issn>2213-1779</issn><issn>2213-1787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUNtKw0AQXUSxpfYHfJA8-pJ0b9lMfBBC7Q3qBW_gU9hkN3ZLmtRsIvTvXbEWnZcznDlzzjAInRMcEEzEaB2s81URUExxgEXg4Aj1KSXMJxFEx4c-intoaO0au4KQAMAp6jGGMSeE99HkSeZdZtrGlKNXWVrZtLK68u701jE7aypvUa2ME5i68kLvTcvGeknR6sZ7SB6Tm8Xs1p9Pz9BJ4Zb1cI8D9DKdPI_n_vJ-thgnS39LhWh9lcWY5lirOIoxFCA0kSBUEQos4iyPJCgS5lQrTjjHmlPKABTjEGMVKZmxAbr-8d122UarXFdtI8vU3bqRzS6tpUn_TyqzSt_rzxSARUBDZ3C5N2jqj07bNt0Ym-uylJWuO5tSzsGFY_EtvfibdQj5_R37Aj7bceA</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Docherty, Kieran F</creator><creator>Vaduganathan, Muthiah</creator><creator>Solomon, Scott D</creator><creator>McMurray, John J V</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202010</creationdate><title>Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF</title><author>Docherty, Kieran F ; Vaduganathan, Muthiah ; Solomon, Scott D ; McMurray, John J V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-db902c0ed97908f86e1a86df56069bc7a8d15c2ed41440e422388d34890d7dab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aminobutyrates</topic><topic>Angiotensin Receptor Antagonists - therapeutic use</topic><topic>Biphenyl Compounds</topic><topic>Drug Combinations</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Neprilysin - therapeutic use</topic><topic>Stroke Volume</topic><topic>Valsartan - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Docherty, Kieran F</creatorcontrib><creatorcontrib>Vaduganathan, Muthiah</creatorcontrib><creatorcontrib>Solomon, Scott D</creatorcontrib><creatorcontrib>McMurray, John J V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JACC. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Docherty, Kieran F</au><au>Vaduganathan, Muthiah</au><au>Solomon, Scott D</au><au>McMurray, John J V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF</atitle><jtitle>JACC. Heart failure</jtitle><addtitle>JACC Heart Fail</addtitle><date>2020-10</date><risdate>2020</risdate><volume>8</volume><issue>10</issue><spage>800</spage><epage>810</epage><pages>800-810</pages><issn>2213-1779</issn><eissn>2213-1787</eissn><abstract>Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard angiotensin-converting enzyme inhibitor. In the 5 years since the publication of the results of PARADIGM-HF, further insight has been gained into integrating a neprilysin inhibitor into a comprehensive multidrug regimen, including a renin-angiotensin aldosterone system (RAS) blocker. This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integration of sacubitril/valsartan among patients with heart failure with reduced ejection fraction.</abstract><cop>United States</cop><pmid>33004114</pmid><doi>10.1016/j.jchf.2020.06.020</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-1779 |
| ispartof | JACC. Heart failure, 2020-10, Vol.8 (10), p.800-810 |
| issn | 2213-1779 2213-1787 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837825 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aminobutyrates Angiotensin Receptor Antagonists - therapeutic use Biphenyl Compounds Drug Combinations Heart Failure - drug therapy Humans Neprilysin - therapeutic use Stroke Volume Valsartan - therapeutic use |
| title | Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A44%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sacubitril/Valsartan:%20Neprilysin%20Inhibition%205%20Years%20After%20PARADIGM-HF&rft.jtitle=JACC.%20Heart%20failure&rft.au=Docherty,%20Kieran%20F&rft.date=2020-10&rft.volume=8&rft.issue=10&rft.spage=800&rft.epage=810&rft.pages=800-810&rft.issn=2213-1779&rft.eissn=2213-1787&rft_id=info:doi/10.1016/j.jchf.2020.06.020&rft_dat=%3Cproquest_pubme%3E2448414065%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448414065&rft_id=info:pmid/33004114&rfr_iscdi=true |